Fungicidal versus fungistatic: What's in a word?

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 6, 2008, Pages 927-935

  Lewis II, James S ^a,b   Graybill, John R ^b  

^a University Health System   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

Author keywords

Aspergillus; Candida; Cryptococcus; Fungicidal; Fungistatic; Susceptibility testing

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; FUNGICIDE; ITRACONAZOLE; MICAFUNGIN; PLACEBO; POSACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; EARLY DIAGNOSIS; FUNGAL VIABILITY; FUNGICIDAL ACTIVITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; REVIEW; TOXICITY;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CLINICAL TRIALS AS TOPIC; CRYPTOCOCCOSIS; CRYPTOCOCCUS; ECHINOCANDINS; HUMANS; MENINGITIS, CRYPTOCOCCAL; MICROBIOLOGICAL TECHNIQUES; POLYENES; TRIAZOLES;

EID: 42649108421     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.6.927     Document Type: Review

References (43)

1. Manavathu E. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles, and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother 2004;53:386-9
2. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998;42:3018-21
3. Rubio C, Ramirez De Ocariz I, Gil J, et al. Potential fungicidal effect of voriconazole against Candida spp. Int J Antimicrob Agents 2005;25:264-7
4. Espinel-Ingroff A. Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole. Antimicrob Agents Chemother 2001;45:605-7
5. Lass-Florl C, Nagl M, Speth C, et al. Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob Agents Chemother 2001;45:124-8
6. Krishnan S, Manavathu E, Chandrasekar PH. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus. J Antimicrob Chemother 2005;55:914-20
7. Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002;46:3001-12
8. Kurtz MB, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob Agents Chemother 1994;38:1480-9
9. Petraitis V, Petratiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2002;187:183443
10. Bowman JC, Abruzzo GK, Flattery AM, et al. Effect of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans. Antimicrob Agents Chemother 2006;50:4202-5
11. Van Vianen W, De Marie S, Ten Kate MT, et al. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 2006;57:732-40
12. Bowman JC, Abruzzo GK, Anderson JW, et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001;45:3474-81
13. Maccallum DM, Whyte JA, Odds FC. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 2005;49:3697-701
14. Gonzalez G, Tijerina R, Najvar L, et al. Correlation between antifungal susceptibilities of Coccidioides immitis (CI) in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother 2001;45:1854-9
15. Pfaller MA, Sheehan DJ, Rex JH. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev 2004;17:268-80
16. Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med 1992;113:183-7
17. Van Der Horst C, Saag M, Cloud G, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997;337:15-21
18. Barchiesi F, Schimizzi AM, Caselli F, et al. Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother 2000;44:2435-41
19. Larsen RA, Bauer M, Thomas AM, Graybill JR. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis. Antimicrob Agents Chemother 2004;48:985-91
20. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004;363:1764-7
21. Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001;39:3254-9
22. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-89
23. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new 'gold standard'. Clin Infect Dis 2003;37:415-25
24. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30
25. Rex JH, Pappas P, Karchmer AW. A randomized and blinded multicenter-trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. Clin Infect Dis 2003;36:1221-8
26. Schaffner A, Frick PG. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis 1985;151:902-10
27. Kontoyiannis DP, Lewis RE, Sagar N, et al. Itraconazole-Amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy. Antimicrob Agents Chemother 2000;44:2915-8
28. Kontoyiannis DP. Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis. Clin Infect Dis 2002;34:1281-3
29. Kontoyiannis DP, Lewis RE. Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol 2004;126:165-75
30. Lewis RE, Prince RA, Chi J, Kontoyiannis DP. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2002;46:3208-14
31. Polak AM, Scholer HJ, Wall M. Combination therapy of experimental candidiasis, cryptococcosis, and aspergillosis in mice. Chemotherapy 1982;28:461-79
32. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9
33. Kuse E, Chetchotisakd P, Da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candisosis: a Phase III randomized double-blind trial. Lancet 2007;369:1519-27
34. Reboli A, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356:2472-82
35. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003;36:1445-57
36. Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006;42:1171-8
37. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis - disease spectrum, treatment practices, and outcomes. Medicine 2000;79:250-60
38. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15
39. Patterson TF, Boucher HW, Herbrecht R, et al. Strategy of following voriconazole versus amphotericin B with other licensed antifungal thersapy for primary treatment of invasive aspergillosis: impact of other therapy on outcome. Clin Infect Dis 2005;41:1448-52
40. Smith J, Safdar N, Kansinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50:1570-2
41. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12
42. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial). Clin Infect Dis 2007;44:1289-97
43. Lass-Florl C, Speth C, Kofler G, et al. Effect of increasing inoculum sizes of Aspergillus hyphae on MICs and MFCs of antifungal agents by broth microdilution method. Int J Antimicrob Agents 2003;21:229-33